<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Greater occipital nerve block efficacy in COVID-19 associated headache: a preliminary study

dc.contributor.authorKaradas, Omer
dc.contributor.authorGul, Hakan Levent
dc.contributor.authorOzturk, Bilgin
dc.contributor.authorSonkaya, Ali Riza
dc.contributor.authorOzon, Akcay Ovunc
dc.contributor.authorShafiyev, Javid
dc.contributor.authorSir, Ender
dc.date.accessioned2026-10-09T21:51:39Z
dc.date.issued2021
dc.departmentYüksek İhtisas Üniversitesi
dc.description.abstractCOVID-19 is an infection caused by the new coronavirus SARS-CoV-2. Headache is one of the most common neurological findings. In the treatment of various chronic headaches, the greater occipital nerve (GON) block is often used as a safe and effective method. The aim of our study was to investigate the effectiveness of the GON block in the treatment of headaches observed in COVID-19 patients. Between March and May 2020, 27 patients (with laboratory-confirmed 2019-nCoV infection by next-generation sequencing confirmation of real-time PCR) that had moderate or severe headache associated with COVID-19 and treated with a single session of GON block were retrospectively analyzed. The visual analogue scale (VAS) values and the number of analgesic usage of patients were recorded before and after the blockade on the 1st and 10th days. Fifteen (55.6%) patients included in the study were male and twelve (44.4%) were female. In terms of VAS values, the difference between pre-treatment and post-treatment values on the 1st and 10th days was found statistically significant. Likewise, the difference between analgesic use before and after the procedure was statistically significant. GON block appears to be an effective pain management method in COVID-19 related headache, and it revealed promising reductions in pain scores and analgesic usage. As well as we know, this is the first study of COVID-19 associated headache treated with GON blockade. More long term and well-designed prospective studies with more participants are needed to better define this headache and develop effective treatment strategies.
dc.identifier.doi10.21307/ane-2021-041
dc.identifier.endpage392
dc.identifier.issn0065-1400
dc.identifier.issn1689-0035
dc.identifier.issue4
dc.identifier.orcid0000-0003-2628-135X
dc.identifier.orcid0000-0001-8659-6607
dc.identifier.orcid0000-0002-8899-9925
dc.identifier.orcid0000-0002-3334-979X
dc.identifier.pmid35014987
dc.identifier.scopus2-s2.0-85123288197
dc.identifier.scopusqualityQ4
dc.identifier.startpage386
dc.identifier.urihttps://doi.org/10.21307/ane-2021-041
dc.identifier.urihttps://hdl.handle.net/20.500.12794/3856
dc.identifier.volume81
dc.identifier.wosWOS:000753668300008
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.digerScience Citation Index Expanded (SCI-EXPANDED)
dc.language.isoen
dc.publisherNencki Inst Experimental Biology
dc.relation.ispartofActa Neurobiologiae Experimentalis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260922
dc.subjectCovid-19 Associated Headache
dc.subjectCovid-19
dc.subjectHeadache
dc.subjectGreater Occipital Nerve
dc.subjectOccipital Nerve Blockade
dc.titleGreater occipital nerve block efficacy in COVID-19 associated headache: a preliminary study
dc.typeArticle

Files